Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) Following Raised Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 130.88 +2.26 (1.76%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $128.62 | 52 Week High | $18.39 | |||
| Open | $130.81 | 52 Week Low | $6.96 | |||
| Day High | $130.98 | P/E | N/A | |||
| Day Low | $126.86 | EPS | $-0.58 | |||
| Volume | 1,016,980 | |||||
